InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Discover the complete record of transactions filed by Namouni Fouad, Président et Directeur de la Recherche et Développement. Insider active across 2 companies, notably Aprea Therapeutics, Inc.. In total, 6 reports have been published. Total volume traded: €603k. The latest transaction was filed on 7 March 2022 — Cession. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations6 total
€54,1001,047 shares@ €51.67129.0% of flow
Common Stock
SEC:0001415889-22-002738:0·
015,000 shares0
Common Stock
SEC:0001415889-22-002432:0·
€274,4043,241 shares@ €84.6665100.0% of flow
Common Stock
SEC:0001179110-21-009297·
€274,4043,241 shares@ €84.666545.5% of flow
Common Stock
SEC:0001179110-21-009297:0·
04,610 shares0
Common Stock
SEC:0001567619-21-012871·
04,610 shares0
Common Stock
SEC:0001567619-21-012871:0·
6 of 6 declarations
About Namouni Fouad
Fouad Namouni is the Director, President of R & D at Aprea Therapeutics, Inc. and Blueprint Medicines Corp. He oversees research and development initiatives, playing a key role in innovation and the development of new products.
